Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Longboard Pharmaceuticals (LBPH)
NASDAQ:LBPH
RESEARCH TOOLSreports
Holding LBPH?
Track your performance easily
LBPH Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$3.60 - $59.95
Previous Close$59.65
Volume1.50M
Average Volume (3M)1.63M
Market Cap
$2.32B
Enterprise Value$2.02B
Total Cash (Recent Filing)$304.87M
Total Debt (Recent Filing)$3.86M
Price to Earnings (P/E)―
Beta-0.80
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.16
Shares Outstanding38,899,521
10 Day Avg. Volume923,313
30 Day Avg. Volume1,628,320
Standard Deviation0.48
R-Squared0.01
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)7.88
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-30.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-30.33
Forecast
1Y Price Target
$63.33Price Target Upside5.90% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering7
Longboard Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Acquisition And Financial StabilityThe acquisition of Longboard Pharmaceuticals by Lundbeck for $60 per share is the biggest acquisition in Lundbeck's history, funded with existing cash resources and bank financing, showing financial stability in executing the deal.
Drug Development And Market PotentialBexicaserin is positioned for success in epilepsy with blockbuster potential, supported by an expanded Phase 3 program and a Breakthrough Therapy Designation granted by the FDA.
Market Confidence And Stock PerformanceAnalyst reiterates a Buy rating on LBPH shares, with an increased price target to $80 from $60, reflecting confidence in the program's potential.
Bears Say
Investor ConcernsInvestor concerns may have driven the deal to consummate earlier than expected, due to a lack of material value-creating catalysts for Longboard Pharmaceuticals over the next 12-18 months.
Revenue EstimatesUpdated revenue estimates reflect Lundbeck's guidance, which calls for estimated global peak sales between $1.5B-$2.0B, lower than the prior estimate of $2.6B.
Stock RatingThe stock rating for Longboard Pharmaceuticals has been downgraded to Neutral.
---
Ownership Overview
1.35% Insiders
28.06% Mutual Funds
3.22% Other Institutional Investors
55.96% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LBPH FAQ
What was Longboard Pharmaceuticals’s price range in the past 12 months?
Longboard Pharmaceuticals lowest stock price was $3.60 and its highest was $59.95 in the past 12 months.
What is Longboard Pharmaceuticals’s market cap?
Currently, no data Available
When is Longboard Pharmaceuticals’s upcoming earnings report date?
Longboard Pharmaceuticals’s upcoming earnings report date is Feb 27, 2025 which is in 110 days.
How were Longboard Pharmaceuticals’s earnings last quarter?
Currently, no data Available
Is Longboard Pharmaceuticals overvalued?
According to Wall Street analysts Longboard Pharmaceuticals’s price is currently Undervalued.
Does Longboard Pharmaceuticals pay dividends?
Longboard Pharmaceuticals does not currently pay dividends.
What is Longboard Pharmaceuticals’s EPS estimate?
Longboard Pharmaceuticals’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Longboard Pharmaceuticals have?
Longboard Pharmaceuticals has 34,419,537 shares outstanding.
What happened to Longboard Pharmaceuticals’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Longboard Pharmaceuticals?
Among the largest hedge funds holding Longboard Pharmaceuticals’s share is RA Capital Management. It holds Longboard Pharmaceuticals’s shares valued at 89M.
---
Longboard Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.33 (5.90% Upside)
$63.33 (5.90% Upside)
Blogger Sentiment
Neutral
LBPH Sentiment 50%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 2.1M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 13.2%
Last 30 Days ▼ 13.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
980.61%
12-Months-Change
Fundamentals
Return on Equity
-36.71%
Trailing 12-Months
Asset Growth
372.50%
Trailing 12-Months
Company Description
Longboard Pharmaceuticals
Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. Its pipeline includes LP352, LP143, and LP659.
---
LBPH Earnings Call
Q2 2024
0:00 / 0:00
---
LBPH Stock 12 Month Forecast
Average Price Target
$63.33
▲(5.90% Upside)
Technical Analysis
Aquestive Therapeutics
―
Kiniksa Pharmaceuticals
―
Pliant Therapeutics
―
Bioxcel Therapeutics
―
Best Analysts Covering LBPH
1 Year
1 Year Success Rate
21/21 ratings generated profit
1 Year Average Return
+202.82%
reiterated a buy rating 26 days ago
Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +202.82% per trade.
---